Penumbra (PEN) – Investment Analysts’ Weekly Ratings Changes

Penumbra (NYSE: PEN) has recently received a number of price target changes and ratings updates:

• 12/22/2025 – Penumbra had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 12/20/2025 – Penumbra was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 12/18/2025 – Penumbra had its price target raised by analysts at Truist Financial Corporation from $312.00 to $370.00. They now have a “buy” rating on the stock.
• 12/18/2025 – Penumbra was upgraded by analysts at JPMorgan Chase & Co. from a “neutral” rating to an “overweight” rating. They now have a $370.00 price target on the stock, up previously from $275.00.
• 12/17/2025 – Penumbra had its “outperform” rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $355.00 price target on the stock.
• 12/17/2025 – Penumbra had its price target raised by analysts at Canaccord Genuity Group Inc. from $355.00 to $359.00. They now have a “buy” rating on the stock.
• 12/17/2025 – Penumbra had its price target raised by analysts at Needham & Company LLC from $326.00 to $388.00. They now have a “buy” rating on the stock.
• 12/16/2025 – Penumbra was given a new $345.00 price target on by analysts at Robert W. Baird.
• 12/15/2025 – Penumbra had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 12/11/2025 – Penumbra was upgraded by analysts at Citigroup Inc. from a “neutral” rating to a “buy” rating. They now have a $350.00 price target on the stock, up previously from $285.00.
• 12/8/2025 – Penumbra had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 11/25/2025 – Penumbra had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/19/2025 – Penumbra had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/18/2025 – Penumbra is now covered by analysts at Wells Fargo & Company. They set an “underweight” rating on the stock.
• 11/6/2025 – Penumbra had its “outperform” rating reaffirmed by analysts at Evercore ISI. They now have a $286.00 price target on the stock.
• 11/6/2025 – Penumbra had its price target raised by analysts at Canaccord Genuity Group Inc. from $350.00 to $355.00. They now have a “buy” rating on the stock.
• 11/6/2025 – Penumbra had its price target raised by analysts at JPMorgan Chase & Co. from $265.00 to $275.00. They now have a “neutral” rating on the stock.
• 11/1/2025 – Penumbra was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.

Insider Transactions at Penumbra

In related news, EVP Johanna Roberts sold 1,800 shares of the business’s stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $300.06, for a total value of $540,108.00. Following the completion of the sale, the executive vice president directly owned 64,736 shares in the company, valued at $19,424,684.16. The trade was a 2.71% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Arani Bose sold 15,000 shares of the company’s stock in a transaction on Thursday, December 11th. The shares were sold at an average price of $308.82, for a total value of $4,632,300.00. Following the completion of the transaction, the director directly owned 258,462 shares in the company, valued at approximately $79,818,234.84. This represents a 5.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 34,744 shares of company stock worth $10,387,474. Company insiders own 5.00% of the company’s stock.

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.